Search Results Label

Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.

https://www.seqirus.us/expertise/influenza/pandemic-response-solutions

Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives

https://www.seqirus.us/news/seqirus-awarded-us-government-contract-for-two-influenza-vaccines

The FDA has granted approval of multi-dose vial presentation for AUDENZ™ to help protect individuals six months of age and older against influenza A(H5N1) in the event of a pandemic.

https://www.seqirus.us/news/fda-approves-multi-dose-vial-presentation-for-audenz

Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.us/expertise

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news

Seqirus appoints Roberta Duncan as new program lead to drive technology advancement. Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza.

https://www.seqirus.us/news/seqirus-invests-in-self-amplifying-messenger-rna-technology

With FDA approval, FLUCELVAX QUADRIVALENT, the first and only cell-based influenza vaccine in the U.S., is now indicated for everyone eligible to receive an influenza vaccine in the United States.

https://www.seqirus.us/news/seqirus-receives-fda-approval-for-flucelvax-quadrivalent-for-children-6-months-and-older

Seqirus Presents New Data at ESWI 2020 Demonstrating Safety and Immunogenicity of Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine

https://www.seqirus.us/news/seqirus-presents-new-data-at-eswi-2020-demonstrating-safety-and-immunogenicity

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news/seqirus-announces-us-fda-approval-of-pandemic-influenza-vaccine

NEJM study indicates that the seasonal influenza vaccine was effective and produced a sufficient immune response against influenza in children and adolescents ≥2 to <18 years of age

https://www.seqirus.us/news/nejm-study-cell-based-quadrivalent-influenza-vaccine-efficacy-in-children